Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. University of Bologna, Bologna, Italy

Survival: 37.8 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: Italy
City/State/Province: Bologna
Hospital: University of Bologna
Journal: Link
Date: 10/2012

This phase 3 study involved follicular lymphoma patients who were divided into two separate treatment groups. Group A consisted of 103 patients with a median age of 61 years and 51% male. Group B consisted of 98 patients with a median age of 60 years and 43% male.

Patients in group A were treated with the biologic therapy agents bortezomib (a proteasome inhibitor) and rituximab (a monoclonal antibody for CD20 that causes the immune system to attack tumor cells).

Patients in group B were treated with rituximab only.

There were two treatment-related deaths in group A due to septic shock and pneumonia. Grade 3 or higher diarrhea, neutropenia, and infection were also reported.

There was one treatment-related death in group B due to meningitis. Grade 3 or higher infection, neutropenia, and anemia were also reported.

The median overall survival rates for groups A and B were 37.8 and 41.5 months, respectively.

This study was supported by Johnson & Johnson Pharmaceutical Research & Development and Millennium Pharmaceuticals, Inc.

Correspondence: Dr. Pier Luigi Zinzani; email:

E-mail to a Friend Email Physician More Information